TY  - JOUR
TT  - JİNEKOLOJİK ONKOLOJİDE FIRST-LINE KEMOTERAPİDE KULLANILAN KOMBİNASYONLARIN HEMATOLOJİK TOKSİSİTE PROFİLLERİNİN KARŞILAŞTIRILMASI
AU  - Turan, Taner
AU  - Küçükelçi, İltaç
AU  - Özgül, Nejat
AU  - Bozok, Serap
AU  - Boran, Nurettin
AU  - Tulunay, Gökhan
AU  - Kög, İskender
AU  - Köse, M. Faruk
PY  - 2006
DA  - October
JF  - Türk Jinekolojik Onkoloji Dergisi
JO  - TRSGO Dergisi
PB  - Türk Jinekolojik Onkoloji Derneği
WT  - DergiPark
SN  - 2148-5372
SP  - 91
EP  - 96
VL  - 9
IS  - 4
KW  - Kemoterapi
KW  - miyelosüpresyon
N2  - Objective: We aimed to finding the hematologic toxicity profile of chemotherapy combinations and comparing them which are usually used in gynecologic oncology. Materials and Methods: It was analyzed of 885 patients who were given 4600 chemotherapy courses because of gynecologic malignancies between 1993 and 2006. We compared of hemotologic toxicity of Ifosfamide/Adriamicyn/Mesna (IMA), Paclitaxel/Carboplatin (P-Car), Paclitaxel/Cisplatin (P-Cis), Etoposide/Methotrexate/Acti-nomycin D/Cyclophosphamide/Vincristine (EMA/CO), Methotrexate-Folinic Acid (MF) and Cyclophosphamide/Anthracycline (Adriamicyn or Epirubicin)/Platinum (CAP) chemotherapy combinations. Results: Hematologic toxicity profile of IMA was worse then the other protocols. Grade 3-4 leucopenia was occurred in 50.4% of IMA courses. This rate was 8.6% in P-Car, 6.9% in EMA/CO, 4.5% in P-Cis and 1.4% in CAP. Similarly grade 3-4 anemia was seen 4.2% of IMA courses which was most common then the others. Grade 3-4 anemia was observed in 1.3% of EMA/CO courses and this ratio was closest the IMA protocol. There was no difference among the chemotherapy protocols by means of thrombocytopenia. However, thrombocytopenia was more common in IMA and P-Car protocols then the others.Discussion: Myelosuppression is an important side effect. It was causes that adjourn maintenance of the treatment, abandon of treatment and even patients death. The toxicity profiles of chemotherapy protocols are very different. We have to know the adverse effect and its management, of chemotherapeutic agents.
UR  - https://dergipark.org.tr/en/pub/trsgo/issue//404415
L1  - https://dergipark.org.tr/en/download/article-file/439161
ER  -